LKFT biotech catalysts & pipeline

OM336 (gamgertamig) — Topline data

2027

Gamgertamig has been granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of AIHA and ITP and is expected to enter registrational studies as early as 2027.